Strs Ohio Krystal Biotech, Inc. Transaction History

Strs Ohio

$25.5 Billion
Q3 2024

A detailed history of Strs Ohio transactions in Krystal Biotech, Inc. stock. As of the latest transaction made, Strs Ohio holds 5,000 shares of KRYS stock, worth $984,550. This represents 0.0% of its overall portfolio holdings.

Number of Shares

5,000

Previous 4,200 19.05%

Holding current value

$984,550

Previous $771,000 17.9%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 01, 2024	BUY	$174.7 - $213.66 $139,760 - $170,928	800 Added 19.05%	5,000 $909,000
Q2 2024 Aug 05, 2024	BUY	$153.12 - $183.64 $306,240 - $367,280	2,000 Added 90.91%	4,200 $771,000
Q1 2024 May 13, 2024	SELL	$108.01 - $179.35 $367,234 - $609,790	-3,400 Reduced 60.71%	2,200 $391,000
Q4 2023 Jan 30, 2024	SELL	$96.0 - $128.29 $76,800 - $102,632	-800 Reduced 12.5%	5,600 $694,000
Q3 2023 Oct 26, 2023	BUY	$108.51 - $130.22 $379,785 - $455,770	3,500 Added 120.69%	6,400 $742,000
Q2 2023 Jul 31, 2023	BUY	$78.48 - $130.32 $125,568 - $208,512	1,600 Added 123.08%	2,900 $340,000
Q1 2023 Aug 02, 2023	SELL	$72.39 - $84.27 $115,824 - $134,832	-1,600 Reduced 55.17%	1,300 $104,000
Q1 2023 Apr 27, 2023	SELL	$72.39 - $84.27 $202,692 - $235,956	-2,800 Reduced 68.29%	1,300 $104,000
Q2 2022 Jul 25, 2022	BUY	$48.93 - $73.47 $9,786 - $14,694	200 Added 5.13%	4,100 $269,000
Q2 2021 Jul 26, 2021	BUY	$62.14 - $81.82 $242,346 - $319,098	3,900 New	3,900 $265,000
Q3 2020 Dec 14, 2020	SELL	$37.76 - $48.49 $86,848 - $111,527	-2,300 Closed	0 $0
Q2 2019 Jul 25, 2019	BUY	$27.2 - $41.2 $62,560 - $94,760	2,300 New	2,300 $92,000

Others Institutions Holding KRYS

# of Institutions

311

Shares Held

24.4M

Call Options Held

483K

Put Options Held

364K

View Full List

About Krystal Biotech, Inc.

Ticker KRYS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,664,300
Market Cap $5.05B
Description
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...

More about KRYS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Strs Ohio, based on Form 13F filings with the SEC.

News

Stay updated on Strs Ohio with notifications on news.

Account